TITLE

GlaxoSmithKline receives FDA approvable letter for Wellbutrin XL

PUB. DATE
August 2003
SOURCE
PharmaWatch: CNS;August 2003, Vol. 2 Issue 8, p10
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Reports on the approval of the antidepressant Wellbutrin XL tablets of GlaxoSmithKline PLC by the U.S. Food and Drug Administration. Increase in the treatment options for adults with depression; License agreement between the firm and Biovail Corp.; Efforts of the company to work with the agency to resolve outstanding issues.
ACCESSION #
13860129

 

Related Articles

  • Biovail shares depressed on Wellbutrin generic filing.  // PharmaWatch: CNS;January 2005, Vol. 4 Issue 1, p10 

    Reports that Biovail Corp.'s shares have hit a one-year low after it confirmed that Anchen Pharmaceuticals company had submitted an abbreviated new drug application to the U.S. Food and Drug Administration to market a generic version of antidepressant medication Wellbutrin XL. Formulations of...

  • Biovail files NDA for novel dosage form of anti-depressant.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p12 

    Reports on the acceptance of the U.S. Food and Drug Administration to Biovail Corp.'s submission of a new drug application for a novel dosage format of citalopram for the treatment of depression. Product offering; Characterization of citalopram hydrobomide; Market penetration of citalopram.

  • Regulatory Update: GSK and XenoPort Submit Supplemental New Drug Application to FDA for Horizant(tm) in Postherpetic Neuralgia.  // Biomedical Market Newsletter;8/12/2011, Vol. 21, p375 

    The article reports that GlaxoSmithKline (GSK) and XenoPort Inc. have submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA). It states that the sNDA requests for the approval of Horizantâ„¢ (gabapentin enacarbil) extended-release tablets for...

  • CNS News Round-Up.  // PharmaWatch: CNS;Jun2009, Vol. 8 Issue 6, p2 

    The article offers world news briefs related to the pharmaceutical industry. The U.S. marketing rights to GlaxoSmithKline's (GSK) Wellbutrin XL tablets have been acquired by Biovail Corp. for £510 million. The orally disintegrating version of Lamictal from GSK has been approved by the U.S....

  • Oncology market: Cytotoxics face biotech challenge.  // PharmaWatch: Cancer;April 2003, Vol. 2 Issue 4, p22 

    Reports that the oncology market has been dominated by cytotoxic treatments. Sales performance of Gleevec from Novartis AG; Recommendation of Bexxar from Corixa Corp. and GlaxoSmithKline PLC for approval by the U.S. Food and Drug Administration; Need of biotechnology companies for licensing...

  • Cardizem LA.  // Formulary;May2004, Vol. 39 Issue 5, p239 

    Provides information on Biovail Corp.'s extended-release calcium antagonist Cardizem LA, which has been approved by the U.S. Food and Drug Administration for the treatment of chronic stable angina.

  • Extended-Release Metformin Combo Drug Given the Green Light. Trecroci, D. // Diabetes Health;Dec2005, Vol. 14 Issue 12, p19 

    Reports on the approval of the drug Glumetza, a formulation of metformin hydrochloride manufactured by Biovail, by the U.S. Food and Drug Administration. Use of the drug for the treatment of type 2 diabetes; Potential advantages of the drug; Common side effects of the drug.

  • Extended-release formation of metformin OK'd.  // Drug Topics;6/20/2005, Vol. 149 Issue 12, p8 

    Reports on the approval of Biovail Corp.'s Glumetz, a once-daily, extended-release formulation of metformin that is indicated for the treatment of Type 2 diabetes, by the U.S. Food and Drug Administration.

  • Biovail files NDA for pain drug Ralivia.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p13 

    Focuses on the submission of a new drug application to the U.S. Food and Drug Administration by Biovail Corp. for Ralivia Flashdose for the treatment of moderate to severe pain. Description of Ralivia Flashdose; Provision of choice of administration with or without water; Benefit to patients...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics